Wellington Management Co. LLP recently announced the acquisition of new stake in Arena Pharmaceuticals Inc. (NASDAQ:ARNA). The institutional investor has increased its shareholding in the Healthcare company by 1.60% to 4.75 million shares with purchase of 74768.0 shares. This fresh investment now brings its stake to 8.51% valued currently at $283.95 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.11 million to 4.58 million shares. And SSgA Funds Management, Inc. has lifted its position by 2.38% or 43910.0 shares – to 1.89 million shares.
With over 0.5 million Arena Pharmaceuticals Inc. (ARNA) shares trading Thursday and a closing price of $63.10 on the day, the dollar volume was approximately $31.71 million. The shares have shown a negative weekly performance of -3.87% and its price on 07/02/20 gained nearly 1.01%. Currently, there are 56.66M common shares owned by the public and among those 50.26M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 12 analysts who have offered their price forecasts for ARNA have a consensus price objective of $76.25. The analysts have set the share’s price value over the next 12 months at a high of $95.00 and a low of $60.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Arena Pharmaceuticals Inc. stock is 1.60 for the next 12 months. The average price target is 18.92% above its last price level and an upside to the estimated low will see the stock lose -5.17% over that period. But an upside of 33.58% will see the stock hit the forecast high price target while mean target price for the stock is $76.00.
Insiders at the company have transacted a total of 66 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 37 of these insider trades were purchases, accounting for 413,727 shares. Insider sales of the common stock occurred on 29 occasions, with total insider shares sold totaling 389,620 shares.
The top 3 mutual fund holders in Arena Pharmaceuticals Inc. are Vanguard Total Stock Market Index, Vanguard Small Cap Index Fund, and iShares Russell 2000 ETF. Vanguard Total Stock Market Index owns 1.61 million shares of the company’s stock, all valued at over $96.42 million. The company bought an additional 0.17 million shares recently to bring their total holdings to about 2.89% of the shares outstanding. Vanguard Small Cap Index Fund bought 0.14 million shares to see its total holdings expand to 1.45 million shares valued at over $86.46 million and representing 2.59% of the shares outstanding. iShares Russell 2000 ETF bought 11766.0 shares to bring its total holdings to over 1.18 million shares at a value of $70.29 million. iShares Russell 2000 ETF now owns shares totaling to 2.11% of the shares outstanding.
Shares of Arena Pharmaceuticals Inc. (NASDAQ: ARNA) opened at $63.21, up $0.74 from a prior closing price of $62.47. However, the script later closed the day at $63.10, up 1.01%. The company’s stock has a 5-day price change of -3.87% and 43.44% over the past three months. ARNA shares are trading 38.93% year to date (YTD), with the 12-month market performance up to 1.51% higher. It has a 12-month low price of $32.95 and touched a high of $69.75 over the same period. Currently, 0.5 million shares have been traded, compared to an average intraday trading volume of 786.74K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.16%, 9.90%, and 27.63% respectively.
Institutional ownership of Arena Pharmaceuticals Inc. (NASDAQ: ARNA) shares accounts for 80.20% of the company’s 56.66M shares outstanding. Mutual fund holders own 34.62%, while other institutional holders and individual stakeholders account for 48.45% and 0.23% respectively.
It has a market capitalization of $3.54B and a beta (3y monthly) value of 1.46. The stock’s earnings-per-share (ttm) stands at -$6.46. The company has a Quick Ratio of 18.70 with the debt-to-equity ratio at 0.05. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.10% over the week and 4.90% over the month.
Analysts forecast that Arena Pharmaceuticals Inc. (ARNA) will achieve an EPS of -$2.06 for the current quarter, -$2.21 for the next quarter and -$8.18 for 2021. The lowest estimate earnings-per-share for the quarter is -$2.23 while analysts give the company a high EPS estimate of -$1.81. Comparatively, EPS for the current quarter was -$1.24 a year ago. Earnings per share for the fiscal year are expected to decrease by -210.90%, and 4.10% over the next financial year. EPS over the next five years should compared to 36.80% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 12 brokerage firm advisors rate Arena Pharmaceuticals Inc. (ARNA) as a “Strong Buy” at a consensus score of 1.60. Specifically, 12 Wall Street analysts polled rate the stock as a buy, while 0 of the 12 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ARNA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 29, 2020, with the firm’s price target at $90. Jefferies coverage for the Arena Pharmaceuticals Inc. (ARNA) stock in a research note released on May 18, 2020 offered a Buy rating with a price target of $62. Guggenheim was of a view on March 31, 2020 that the stock is Buy, while BofA/Merrill gave the stock Buy rating on March 26, 2020, issuing a price target of $47- $56. JP Morgan on their part issued Overweight rating on January 31, 2020.
